Abstract 3387
Background
Patients undergoing haematopoietic stem cell transplantation (HSCT) are often hospitalised in protective isolation in order to reduce the risk of dangerous infection. However, they could experience isolation-related suffering, problems in relationships with others, and difficulties in relating to themselves. Oncology nurses might play an important role in mitigating perceived isolation and in providing emotional support. The aim of this study was to identify which factors can influence the level of emotional support from nurses perceived by patients with haematological malignancies undergoing HSCT in isolation.
Methods
A multicentre prospective study was conducted in 10 haematology centres of the Italian Group of stem cell transplant (GITMO). Emotional support from nurses was measured between day +7 and +9 post-transplant using the Scale Experiences on the Newcastle Satisfaction with Nurses Scale. Multiple linear regression analysis was performed.
Results
The participants were 186 adult patients receiving autologous (48%) or allogeneic (52%) HSCT in protective isolation. They were mainly male (61.6%) with a mean age of 50.1 (SD = 13.4; range=19-71). The regression model explained 23% of the total variance (p < .001) (Table). Sex, pain level, double room, satisfaction with information received before HSCT, and patients to nurse ratio were independently associated with emotional support from nurses.Table: CN56
Regression model predicting perceived emotional support from nurses (n = 186)
| β | 95% CI | P | |
|---|---|---|---|
| Sex (female) | .193 | (.056; .332) | .006 |
| Pain level | -.147 | (-.287; -.007) | .040 |
| First HSCT | .099 | (-.038; .234) | .158 |
| Double room | .242 | (.098; .378) | .001 |
| Satisfaction with info | .403 | (.264; .547) | <.001 |
| Patients to nurse | -.168 | (-.316; -.027) | .021 |
| P | <.001 |
Conclusions
Patients who reported high emotional support from nurses were female, with low pain, satisfied with information received, and hospitalised in double room in a ward with a low patients to nurse ratio. It is crucial to reduce the patients to nurse ratio in order to promote the role of nurses in providing emotional support.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Campus Bio-Medico di Roma University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract